Friday, September 22, 2023
Medscape, LLC requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated. Others involved in the planning of this activity have no relevant financial relationships.
Consultant in Diabetes and Endocrinology at Portsmouth Hospitals NHS Trust
National Specialty Advisor in Diabetes with NHS England
Portsmouth, United Kingdom
This activity has been peer reviewed and the reviewer has no relevant financial relationships.
Physicians - maximum of 0.25 AMA PRA Category 1 Credit(s)™
This educational activity is intended for an international audience of non-US and non-UK diabetologists/endocrinologists, primary care physicians and other healthcare professionals involved in the management of diabetes.
The goal of this activity is for learners to be better able to understand the latest technological advances designed to improve insulin regimen management and treatment adherence in patients with diabetes.
Upon completion of this activity, participants will:
Medscape, LLC requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated. Others involved in the planning of this activity have no relevant financial relationships.
Consultant in Diabetes and Endocrinology at Portsmouth Hospitals NHS Trust
National Specialty Advisor in Diabetes with NHS England
Portsmouth, United Kingdom
This activity has been peer reviewed and the reviewer has no relevant financial relationships.
Medscape, LLC designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.
For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]
There are no fees for participating in or receiving credit for this online educational activity. For information on applicability
and acceptance of continuing education credit for this activity, please consult your professional licensing board.
This activity is designed to be completed within the time designated on the title page; physicians should claim only those
credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the
activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 70% on the post-test.
Follow these steps to earn CME/CE credit*:
You may now view or print the certificate from your CME/CE Tracker. You may print the certificate, but you cannot alter it.
Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period, you can print
out the tally as well as the certificates from the CME/CE Tracker.
*The credit that you receive is based on your user profile.
CME Released: 12/27/2022
Valid for credit through: 12/27/2023, 11:59 PM EST
processing....
Peter has a 15-year history of T2D. His HbA1c is 8.7% and he’s being treated with metformin and basal-bolus insulin regimen [degludec + aspart]. He is overweight with a BMI of 27 kg/m2, and he has dyslipidemia (controlled on statin), hypertension (controlled on ACE inhibitor/diuretic). His eGFR is 78 mL/min, and he is showing early signs of retinopathy and peripheral neuropathy.
